Sepoy-logo
No Result
View All Result
Tuesday, December 5, 2023
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Research shows benefit of dapagliflozin for heart failure patients regardless of ejection fraction

Nicholas by Nicholas
August 29, 2022
in Health
0

Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late-breaking research presented in a Hot Line session today at ESC Congress 2022.

This pre-specified patient-level meta-analysis combined the DAPA-HF and DELIVER trials of the SGLT2 inhibitor dapagliflozin in patients with heart failure. DAPA-HF enrolled patients with reduced ejection fraction (40% or less) and DELIVER enrolled patients with mildly reduced and preserved ejection fraction (above 40%). Both trials randomly allocated participants to dapagliflozin 10 mg once daily or placebo.

The first aim of this analysis was to examine the effect of dapagliflozin on a number of secondary outcomes that each trial alone was not powered to examine. The second aim was to examine if dapagliflozin was effective across the entire range of ejection fraction, since the EMPEROR-Preserved trial previously suggested that the effect of empagliflozin, another SGLT2 inhibitor, may be attenuated in patients with higher ejection fraction.

A total of 11,007 patients were randomised to dapagliflozin or placebo in the two trials. Survival analysis was used to examine the effect of dapagliflozin on death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction, or stroke (major adverse cardiovascular events; MACE).

The average age of participants was 69 years and 35% were women. The median follow up was 1.8 years. Dapagliflozin reduced the risk of death from cardiovascular causes by 14% (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.76-0.97; p=0.01), death from any cause by 10% (HR 0.90; 95% CI 0.82-0.99; p=0.03), total hospital admissions for heart failure by 29% (relative risk [RR] 0.71; 95% CI 0.65-0.78; p<0.001) and MACE by 11% (HR 0.90; 95% CI 0.81-1.00; p=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction for any of the outcomes.

Our findings confirm that all patients with heart failure, regardless of ejection fraction, may benefit from dapagliflozin in addition to any other heart failure therapy they are receiving.”


Pardeep Jhund, Study Author, Professor University of Glasgow, UK

Source:

European Society of Cardiology (ESC)

READ ALSO

Brown seaweed emerges as a potent ally in diabetes control

Study links brisk walking to lower type 2 diabetes risk

Tags: CardiologyHeartHeart FailureHospitalPlaceboResearch

Related Posts

Brown seaweed emerges as a potent ally in diabetes control
Health

Brown seaweed emerges as a potent ally in diabetes control

December 5, 2023
Study links brisk walking to lower type 2 diabetes risk
Health

Study links brisk walking to lower type 2 diabetes risk

December 4, 2023
New decision rule can reduce unnecessary head CT scans in older adults after falls
Health

New decision rule can reduce unnecessary head CT scans in older adults after falls

December 4, 2023
Does immediate parent-infant skin-to-skin contact improve interaction in very preterm babies at 4 months?
Health

Does immediate parent-infant skin-to-skin contact improve interaction in very preterm babies at 4 months?

December 4, 2023
Navigating STXBP1-related disorders: Unraveling clinical and developmental outcomes
Health

Navigating STXBP1-related disorders: Unraveling clinical and developmental outcomes

December 4, 2023
Gut microbe Lactobacillus found to bolster stress resilience, new study reveals
Health

Gut microbe Lactobacillus found to bolster stress resilience, new study reveals

December 4, 2023
Next Post

After fish kills: Environment Minister Lemke insists on stopping the expansion of the Oder

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

POPULAR NEWS

Roblox Is Unbreakable Trello Is this safe?

Roblox Is Unbreakable Trello Is this safe?

November 4, 2022
Discord Registered Games  Discord Registered Gaming You need to join the Club

Discord Registered Games Discord Registered Gaming You need to join the Club

November 4, 2022
How To Chose the Right Data Analytics Program

How To Chose the Right Data Analytics Program

November 4, 2022
Heavy explosion on market square in Halle – three injured

Heavy explosion on market square in Halle – three injured

November 4, 2022

Shivon Zilis Wiki, Height, Age, Boyfriend, Husband, Family, Biography & More

July 11, 2022

EDITOR'S PICK

Tether recommence à faire des prêts en USDT alors qu'il s'était engagé à arrêter cette activité – Pourquoi ?

Tether recommence à faire des prêts en USDT alors qu'il s'était engagé à arrêter cette activité – Pourquoi ?

September 21, 2023
Firmen bekommen keine Förderung mehr für E-Autos

Firmen bekommen keine Förderung mehr für E-Autos

September 1, 2023

Column for life – The summer of my childhood

June 17, 2022

Mail Order Brides Statistics

September 22, 2022

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: [email protected]

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Visual History Archive: Wo die Überlebenden des 7. Oktober sprechen
  • How to Find Your Next High-Quality Wig
  • Brown seaweed emerges as a potent ally in diabetes control

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net

x